The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
January 10, 2022
View Complete Issue         Table of Contents 2019 
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)
Download PDF:   US English
Disclosures & ObjectivesDisclosures & Objectives
Take CME
Exam
View Complete Issue
Send Article Feedback
Med Lett Drugs Ther. 2022 Jan 10;64(1641):e1-5
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
  • F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the 2021-2022 recommendations for antiviral treatment and prophylaxis of seasonal influenza.
 Select a term to see related articles  Antiviral drugs   baloxavir   FluMist   influenza   Influenza vaccine   Neuraminidase inhibitors   Oseltamivir   Peramivir   Rapivab   Relenza   Tamiflu   Xofluza   Zanamivir 

View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022

Download PDF: US English
© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
arrow to previous article
arrow to next article